ACYP1

ACYP1 Full Name

acylphosphatase 1, erythrocyte (common) type

ACYP1 Introduction

Acylphosphatase 1 (ACYP1), also known as muscle acylphosphatase or soluble acylphosphatase, is a small, highly conserved enzyme belonging to the acylphosphatase family, specialized in catalyzing the hydrolysis of acylphosphates—high-energy phosphate compounds—to their corresponding carboxylic acids and inorganic phosphate. Distinguished from other acylphosphatase isoforms, ACYP1 is predominantly expressed in skeletal muscle and cardiac muscle, where it plays a critical role in regulating cellular energy metabolism and phosphate homeostasis. ACYP1 specifically targets acylphosphates such as 1,3-bisphosphoglycerate (1,3-BPG) and acetylphosphate, which are intermediates in glycolysis and energy production pathways. By hydrolyzing these high-energy compounds, ACYP1 helps fine-tune the balance of intracellular phosphate groups and energy carriers, supporting efficient muscle contraction and energy metabolism. Today, ACYP1 is recognized not only as a specialized muscle-specific enzyme but also as a key regulator of muscle energy homeostasis, with profound implications for muscle biology, exercise physiology, and neuromuscular disorders research.

Figure 1.The structure of ACYP1.

ACYP1 in Disease and Therapeutic Relevance
Genetic variations and dysregulation of ACYP1 are associated with neuromuscular disorders and muscle-related pathologies. Reduced ACYP1 expression or activity leads to the accumulation of acylphosphates in muscle cells, disrupting glycolysis and energy production, which contributes to muscle weakness, fatigue, and myopathy. ACYP1 deficiency has been linked to inherited myopathies, characterized by progressive muscle wasting, exercise intolerance, and impaired muscle function. Additionally, ACYP1 dysregulation is associated with cardiac dysfunction, as impaired energy metabolism in cardiac muscle can lead to arrhythmias and heart failure. Common genetic polymorphisms in the ACYP1 gene have been linked to differences in muscle performance and exercise capacity in human populations. ACYP1 holds therapeutic potential for neuromuscular disorders: modulating its activity could restore muscle energy metabolism, improve muscle function, and alleviate symptoms of myopathies. Ongoing research focuses on developing targeted therapies to enhance ACYP1 function in diseased muscle tissues.

ACYP1 as a Diagnostic Biomarker and Therapeutic Target
Due to its tissue-specific expression pattern and its upregulation in certain cancers, ACYP1 has been proposed as a diagnostic and prognostic biomarker. In glioblastoma, high ACYP1 expression correlates with shorter patient survival and resistance to temozolomide (the standard chemotherapy), and measuring ACYP1 levels in tumor biopsies may help identify patients who would benefit from more aggressive treatment regimens. In breast cancer, ACYP1 expression is elevated in triple-negative breast cancer (TNBC) compared to other subtypes, and high ACYP1 is associated with lymph node metastasis and poor prognosis. Immunohistochemical detection of ACYP1 in breast cancer tissues could potentially be used as a prognostic marker, though standardized protocols and large-scale validation studies are lacking. As a therapeutic target, ACYP1 has attracted interest for cancer treatment because its inhibition might selectively kill cancer cells while sparing normal cells (which have lower ACYP1 expression or are less dependent on it). Several small-molecule inhibitors of ACYP1 have been identified through high-throughput screening, including coumarin derivatives and benzoic acid analogs, with IC50 values in the low micromolar range. However, these compounds are not selective for ACYP1 over the closely related ACYP2, and their cytotoxicity in cancer cell lines has been modest. The development of selective ACYP1 inhibitors will require detailed structural information; the crystal structure of human ACYP1 is available (PDB: 1APS, 1SUW), and structure-based drug design approaches are underway. Additionally, because ACYP1 is not essential for survival (Acp1-knockout mice are viable and fertile), its inhibition is unlikely to cause unacceptable on-target toxicity, making it a potentially attractive target for pharmaceutical intervention.

Alternate Names for ACYP1

ACYP1; acylphosphatase 1, erythrocyte (common) type; acylphosphatase-1; acylphosphate phosphohydrolase 1; acylphosphatase, erythrocyte isozyme; acylphosphatase, organ-common type isozyme; ACYPE;